Abstract
The tissue retention of radiocopper afforded by intravenous injection of the proposed blood flow imaging agent, 62Cu-labeled copper(II) pyruvaldehyde bis( N 4-methylthiosemicarbazone) [Cu(PTSM)], is thought to result from reductive decomposition of the copper(II) complex by intracellular sulfhydryls (e.g. glutathione, GSH). To determine if the tissue uptake and retention of this tracer adequately measures perfusion in tissues containing altered GSH concentrations, the biodistribution of copper-67 labeled Cu(PTSM) was determined in GSH-depleted rats. Despite treatment to induce relatively large reductions in tissue GSH levels, it was found that only very small changes in the biodistribution of copper-labeled Cu(PTSM) occurred in the treated rats compared to untreated controls.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
